Table 3. Comparative Cost-Effectiveness of Statin Use for Primary Prevention of Coronary Heart Disease (2016-2025), Relative to Status Quo.

	ATP III	ACC-AHA	Age/Sex-Based
Total Additional Persons Acted On*	8.76 m†	21.0 m	49.9 m
Total Cost	-$10.7 b	-14.6 b	-$26.0 b
Treatment costs ‡	$8.29 b	$21.6 b	$35.0 b
Screening costs§	$2.65 b	$6.36 b	$4.65 b
Savings from events averted	-$19.0 b	-$36.1 b	-$61.1 b
Incident CHD Events Averted	341,000	578,000	999,000
QALYs Saved	253,000	436,000	705,000
Lives Saved	42,300	86,000	135,000
Total Cost per QALY (ICER)	Cost-saving	Cost-saving	Cost-saving
NNT per QALY	35	49	71
NNT per Life Saved	205	245	370

^*Total persons are relative to the status quo scenario.

^†7.6 million started on statins de novo; 1.2 with prior dose intensified.

^‡All costs of treatment (including medication costs).

^§The cost of adverse outcomes; lipid and liver function tests; and physician visits associated with statin use.